Catalyst

Slingshot members are tracking this event:

Cellectis (CLLS) signs agreement with CELLforCURE for the cGMP Manufacturing of UCART123 for Hematological Malignancies

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CLLS

100%

Additional Information

Management Comment Dr. David J.D. Sourdive, Executive Vice President Corporate Development, Cellectis, stated: “The manufacturing campaign for UCART123 consolidates Cellectis’ GMP processes and our expertise in its industrialization while allowing Cellectis to further enhance and improve the manufacturing of its UCART product candidates.”
http://www.cellectis...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 16, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Cgmp, Ucart, Manufacturing, Car-t, Immunotherapy